Results 221 to 230 of about 5,643 (237)

Epigenetic-Targeted Treatments for H3K27M-Mutant Midline Gliomas

2020
Diffuse intrinsic pontine glioma (DIPG) is a lethal midline brainstem tumor that most commonly occurs in children and is genetically defined by substitution of methionine for lysine at site 27 of histone 3 (H3K27M) in the majority of cases. This mutation has since been shown to exert an influence on the posttranslational epigenetic landscape of this ...
Victor M, Lu, David J, Daniels
openaire   +2 more sources

Four methods to analyze H3K27M mutation in diffuse midline gliomas

Pathology - Research and Practice, 2020
The histone H3 K27M mutation has been frequently reported in the majority of diffuse midline gliomas, which is considered as a prognostic and predictive biomarker. A number of different methods and platforms including pyrosequencing (PSQ), sanger sequencing, immunohistochemistry (IHC), Mass array and NGS (Next Generation Sequencing) have been used to ...
Huanying, Zhao, Xiao, Fang, Bing, Xue
openaire   +2 more sources

High frequency of H3K27M immunopositivity in adult thalamic glioblastoma

Neuropathology, 2019
Adult thalamic glioblastomas (GBM) are uncommon tumors with limited available molecular data. One of the reported molecular alterations in these tumors is the H3K27M mutation. It has been documented that H3K27M mutation is found in a high proportion of pediatric thalamic gliomas.
Shilpa Rao, Nandaki N. Kanuri, Vidya Nimbalkar, Arimappamagan Arivazhagan, Vani Santosh   +4 more
openaire   +2 more sources

Histone H3K27M Mutation in Brain Tumors

2020
Histones form chromatin and play a key role in the regulation of gene expression. As an epigenetic information form, histone modifications such as methylation, phosphorylation, acetylation, and ubiquitination are closely related to the regulation of genes.
openaire   +2 more sources

Spinal intramedullary H3K27M mutant glioma with vertebral metastasis: a case report

Child's Nervous System, 2021
A new entity of gliomas, named "diffuse midline glioma (DMG), H3K27M mutant (grade IV)," which represents a specific molecular profile, was introduced to the World Health Organization (WHO) classification 2016 of central nervous system tumors. Many midline localizations have been described for this glioma, and mainly the hypothalamus, pons, thalamus ...
Chafik Handis, Bahattin Tanrıkulu, Ayça Erşen Danyeli, M. Memet Özek   +3 more
openaire   +2 more sources

Detection of H3K27M mutation in cases of brain stem subependymoma

Human Pathology, 2019
Subependymomas are rare, slow-growing, grade I glial tumors of the central nervous system. Recently, diffuse midline gliomas with mutations in the H3.1 or H3.3 genes at the position of amino acid 27, resulting in the replacement of lysine by methionine (K27M), were defined as the new grade IV entity.
Kun, Yao, Zejun, Duan, Yin, Wang, Mingshan, Zhang, Tao, Fan, Bin, Wu, Xueling, Qi   +6 more
openaire   +2 more sources

Thalamic H3K27M altered diffuse midline gliomas: Clinicopathological and outcome analysis

Clinical Neurology and Neurosurgery
Diffuse midline glioma (DMG) is a relatively new entity which was introduced in the fourth edition of the WHO classification of CNS tumours in 2016 and later underwent revision in 2021. It is an infiltrative glioma arising from midline structures, viz., thalamus, spine, and brainstem. Current literature on DMG is based majorly on brainstem lesions, and
Aprajita Chaturvedi, Nishanth Sadashiva, Dhaval Shukla, Subhas Konar, Uday Krishna, Manish Beniwal, Shilpa Rao, Vani Santosh, Jitender Saini, Vikas Vazhayil, AR Prabhuraj, Nupur Pruthi, Arivazhagan Arimappamagan   +12 more
openaire   +2 more sources

PATH-40. CLINICAL CHARACTERIZATION OF H3K27M-MUTANT GLIOMAS

Neuro-Oncology
Abstract Diffuse midline gliomas, H3K27M-altered(DMGs) are a recently defined entity of gliomas, occur in midline, infiltrate diffusely and have poor prognosis. We reviewed our cases of DMGs to describe clinical, pathological, molecular characteristics, retrospectively.
Tatsuya Takezaki, Jun-ichiro Kuroda, Naoki Shinojima, Keitaro Kai, Takahiro Yamamoto, Kenji Fujimoto, Hirotaka Inoue, Hiroyuki Sueyoshi, Keisuke Matsuzaki, Yuki Takeshima, Jin Matsuura, Akitake Mukasa   +11 more
openaire   +1 more source

GD2-Targeting CAR T Cells Show Promise in H3K27M-Mutated Gliomas

Cancer Discovery, 2022
Abstract Three out of four patients treated with GD2-targeting CAR T cells showed radiographic and clinical improvement.
openaire   +2 more sources

H3K27M Vaccine Appears Safe and Immunogenic in Diffuse Midline Glioma

Cancer Discovery, 2023
Abstract An H3K27M-specific vaccine was tolerable and immunogenic in patients with diffuse midline glioma (DMG).
openaire   +1 more source